KW 2449 nthin 8-1 Smad5 and Smad8 activation with

Smad5 and Smad8 activation with greater potency than did dorsomorphin (IC50=5 nM versus 470 nM) while retaining 200-fold selectivity for BMP signaling versus TGF-β signaling (IC50 for TGF-β ≥1

Uptake of Dimesna by OAT1

Coleman RL

Kumanogoh A

KW 2449 nthin 8-1 Smad5 and Smad8 activation withKW 2449 is a novel multikinase inhibitor, which suppresses the growth of leukemia cells with FLT3 mutations or T315I mutated BCR ABL translocation. Recent research showed that HDACIs increase KW 2449 lethality in Bcr Abl(+) cells in association with inhibition of Bcr Abl, generation of ROS, and induction of DNA damage. This strategy preferentially targets primary Bcr Abl(+) hematopoietic cells and exhibits enhanced in vivo activity. Combining KW 2449